التفاصيل البيبلوغرافية
| العنوان: |
Evaluation of potential biomarkers for lenvatinib plus pembrolizumab among patients with advanced endometrial cancer: results from Study 111/KEYNOTE-146 |
| المؤلفون: |
Makker, Vicky, Taylor, Matthew H, Aghajanian, Carol, Cohn, Allen L, Brose, Marcia S, Simone, Christopher Di, Cao, Zhu Alexander, Suttner, Leah, Loboda, Andrey, Cristescu, Razvan, Jelinic, Petar, Orlowski, Robert, Dutta, Lea, Matsui, Junji, Dutcus, Corina E, Minoshima, Yukinori, Messing, Mark J |
| المساهمون: |
Eisai Inc., Nutley, NJ, USA, Merck Sharp & Dohme LLC, a subsidiary of Merck & Co., Inc., Rahway, NJ, USA |
| المصدر: |
Journal for ImmunoTherapy of Cancer ; volume 12, issue 1, page e007929 ; ISSN 2051-1426 |
| بيانات النشر: |
BMJ |
| سنة النشر: |
2024 |
| مصطلحات موضوعية: |
Cancer Research, Pharmacology, Oncology, Molecular Medicine, Immunology, Immunology and Allergy |
| الوصف: |
Background Lenvatinib plus pembrolizumab demonstrated clinically meaningful benefit in patients with previously treated advanced endometrial carcinoma in Study 111/KEYNOTE-146 ( NCT02501096 ). In these exploratory analyses from this study, we evaluated the associations between clinical outcomes and gene expression signature scores and descriptively summarized response in biomarker subpopulations defined by tumor mutational burden (TMB) and DNA variants for individual genes of interest. Methods Patients with histologically confirmed metastatic endometrial carcinoma received oral lenvatinib 20 mg once daily plus intravenous pembrolizumab 200 mg every 3 weeks for 35 cycles. Archived formalin-fixed paraffin-embedded tissue was obtained from all patients. T-cell–inflamed gene expression profile (Tcell inf GEP) and 11 other gene signatures were evaluated by RNA sequencing. TMB, hotspot mutations in PIK3CA (oncogene), and deleterious mutations in PTEN and TP53 (tumor suppressor genes) were evaluated by whole-exome sequencing (WES). Results 93 and 79 patients were included in the RNA-sequencing-evaluable and WES-evaluable populations, respectively. No statistically significant associations were observed between any of the RNA-sequencing signature scores and objective response rate or progression-free survival. Area under the receiver operating characteristic curve values for response ranged from 0.39 to 0.54; all 95% CIs included 0.50. Responses were seen regardless of TMB (≥175 or <175 mutations/exome) and mutation status. There were no correlations between Tcell inf GEP and TMB, Tcell inf GEP and microvessel density (MVD), or MVD and TMB. Conclusions This analysis demonstrated efficacy for lenvatinib plus pembrolizumab regardless of biomarker status. Results from this study do not support clinical utility of the evaluated biomarkers. Further investigation of biomarkers for this regimen is warranted. Trial registration number NCT02501096 . |
| نوع الوثيقة: |
article in journal/newspaper |
| اللغة: |
English |
| DOI: |
10.1136/jitc-2023-007929 |
| الإتاحة: |
https://doi.org/10.1136/jitc-2023-007929Test |
| حقوق: |
http://creativecommons.org/licenses/by-nc/4.0Test/ |
| رقم الانضمام: |
edsbas.55DC1A5B |
| قاعدة البيانات: |
BASE |
